Eris Lifesciences バランスシートの健全性
財務の健全性 基準チェック /36
Eris Lifesciencesの総株主資本は₹31.8B 、総負債は₹27.0Bで、負債比率は84.8%となります。総資産と総負債はそれぞれ₹70.2Bと₹38.4Bです。 Eris Lifesciencesの EBIT は₹5.8Bで、利息カバレッジ比率3.6です。現金および短期投資は₹2.4Bです。
主要情報
84.8%
負債資本比率
₹26.95b
負債
| インタレスト・カバレッジ・レシオ | 3.6x |
| 現金 | ₹2.43b |
| エクイティ | ₹31.77b |
| 負債合計 | ₹38.45b |
| 総資産 | ₹70.22b |
財務の健全性に関する最新情報
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Recent updates
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30財務状況分析
短期負債: ERISの 短期資産 ( ₹13.2B ) が 短期負債 ( ₹12.3B ) を超えています。
長期負債: ERISの短期資産 ( ₹13.2B ) は 長期負債 ( ₹26.1B ) をカバーしていません。
デット・ツー・エクイティの歴史と分析
負債レベル: ERISの 純負債対資本比率 ( 77.2% ) は 高い と見なされます。
負債の削減: ERISの負債対資本比率は、過去 5 年間で1%から84.8%に増加しました。
債務返済能力: ERISの負債は 営業キャッシュフロー によって 十分にカバー されています ( 26.2% )。
インタレストカバレッジ: ERISの負債に対する 利息支払い は EBIT ( 3.6 x coverage) によって 十分にカバーされています。